Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 5/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10184345 | 0.96 | PTGDR2 (0.44) | PDE4APDE4BPDE4CPDE4DPTGDR2 | |
| SCHEMBL10184974 | 0.92 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DPTGDR2 | |
| SCHEMBL10184875 | 0.90 | POLB (0.48) | PTGDR2DGAT1 | |
| SCHEMBL10184349 | 0.90 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DPTGDR2 | |
| SCHEMBL10186431 | 0.89 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DDGAT1 | |
| SCHEMBL10184967 | 0.89 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DDGAT1 | |
| SCHEMBL10185076 | 0.89 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DDGAT1 | |
| SCHEMBL10184334 | 0.88 | PTGDR2 (0.46) | PDE4APDE4BPDE4CPDE4DPTGDR2 | |
| SCHEMBL10184318 | 0.87 | PDE4A (0.47) | PDE4APDE4BPDE4CPDE4DPTGDR2 | |
| SCHEMBL10186143 | 0.87 | DGAT1 (0.42) | PDE4APDE4BPDE4CPDE4DPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | PDE4A 1520/4885PDE4B 1283/4885PDE4C 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.